New virus therapy aims to boost immune attack on hard-to-treat cancers
NCT ID NCT05492682
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) will receive the combination. The main goals are to check safety and see if the treatment activates the immune system against tumor markers NY-ESO-1 and MAGE-A3.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Istituto Clinico Humanitas
NOT_YET_RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
IRCCS Ospedale San Raffaele
NOT_YET_RECRUITINGMilan, Italy
Contact Email: •••••@•••••
-
Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS
RECRUITINGCandiolo, Italy
Contact Email: •••••@•••••
-
Krankenhaus Nordwest
ACTIVE_NOT_RECRUITINGFrankfurt, Germany
-
National Center for Tumor Diseases
COMPLETEDHeidelberg, Germany
-
Università di Napoli Federico II
NOT_YET_RECRUITINGNaples, Italy
Contact Email: •••••@•••••
-
Universitätsklinikum Tübingen
COMPLETEDTübingen, Germany
Conditions
Explore the condition pages connected to this study.